Publication

Article

Cardiology Review® Online

February 2014
Volume30
Issue 1

CME Instructions

CME Reviews: Volume 30, No. 1

Release date: February 23, 2014

Expiration date: February 23, 2015

Media used: Internet-based

Estimated time to complete this CME activity: 1 hour

Statement of Need

Cardiovascular disease (CVD) is the leading cause of death in the United States. It is estimated that 83 million American adults have 1 or more forms of CVD. New agents, procedures, and interventions have improved patient outcomes with decreased mortality and morbidity rates. However, as the population ages and as younger adults are developing comorbidities due to unhealthy lifestyles, the patient population at risk for cardiovascular events is increasing.

Care for patients with CVD has become increasingly complex, and community-based cardiologists often struggle to stay up-to-date with the volume of new data. The overall goals of this publication are to provide timely and pertinent original research articles that review current guidelines, practices, and new developments in the field of cardiovascular medicine. The publication also emphasizes preventing CVD by modifying risk factors through such strategies as healthy eating, regular exercise, and avoidance of smoking.

Target Audience

The target audience for this activity is cardiologists.

Learning Objectives

Integrate concepts, theories, novel therapies, and practical skills that allow cardiologists to:

  1. Quantify the impact of 7-day follow-up visits and 30-day readmission rates as part of a hospital quality improvement initiative to lower heart failure readmissions after discharge at the UCONN Heart Failure Center.
  2. Describe the plausible biologic pathways that may contribute to the association between depression and cardiovascular disease.
  3. Explain how a Mediterranean-style diet/AHEI2010 system might lower mortality risk after MI.
  4. Assess the implications of hospital industry consolidation as described by Dafny.
  5. Compare the risks and benefits associated with incretin-based therapies for the treatment of type 2 diabetes.
  6. Interpret data from Criqui et al’s MESA study of coronary artery calcium volume and density and incident cardiovascular events.
  7. Evaluate evidence from Hobl et al’s study of the effect of morphine on clopidogrel concentration and effects.

Financial Disclosure

As a sponsor accredited by the ACCME, it is the policy of Physicians’ Education Resource®, LLC (PER®), to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants prior to the beginning of each CME activity. PER® has identified and resolved all conflicts of interest prior to the release of this activity.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

Sources of Funding

No educational grants from commercial interests were received.

Instructions for Receiving Credit

In order to receive a CME certificate for this activity, participants must

  • Take the pretest and record their answers online at www.cardiology-review.com.
  • Read each review.
  • Take the posttest and record their answers online at www.cardiology-review.com. A passing score of 70% or higher is required to obtain a CME certificate.
  • Complete the CME activity evaluation at www.cardiology-review.com. Participants can immediately download their CME certificates upon successful passing of the posttest and completion of the CME activity evaluation.

Accreditation and Designation of Credit

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Editor-in-Chief

Debabrata Mukherjee, MD, MS, FACC

Chief, Cardiovascular Medicine

Clinical and Research Fellow

Vice Chairman, Department of Internal Medicine

Texas Tech University Health Sciences Center

El Paso, TX

Saurav Chatterjee, MD

Fellow, Cardiovascular Diseases

Division of Cardiology

St Luke’s—Roosevelt Hospital Center

New York, NY

Diana Fancher, DNP, MBA, RN

Chief Nursing Officer,

University Medical Center of El Paso

El Paso, TX

Peter H. Jones, MD

Associate Professor

Center for Cardiovascular Disease Prevention

Baylor College of Medicine, Texas Heart Institute

Houston, TX

Rabab Moshin, MD

Cardiology Fellow

Texas Tech University Health Sciences Center

El Paso, TX

Navin C. Nanda, MD

Distinguished Professor of Medicine and Cardiovascular Disease

Director, Heart Station/Echocardiography Laboratory

University of Alabama at Birmingham

Birmingham, AL

Timir K. Paul, MD, PhD, MPH

Assistant Professor of Medicine

Division of Cardiology

Director, Preventive Medicine and Cardiac Rehabilitation

Quillen College of Medicine

East Tennessee State University

Johnson City, TN

Karla K. Quevedo, MD

Cardiology Fellow

Texas Tech University Health Sciences Center

El Paso, TX

Siddharth Singh, MD

Assistant Professor of Cardiology

University of Alabama at Birmingham

Birmingham, AL

The following individuals have relevant financial relationship(s) with commercial interests to disclose:

Authors: Peter H. Jones, MD- Consultant: Merck, Atherotech Diagnostics Lab

The following individuals have no relevant financial relationships with commercial interests to disclose:

Saurav Chatterjee, MD; Diana Fancher, DNP, MBA, RN; Rabab Mohsin, MD; Navin C. Nanada, MD; Timir K. Paul, MD, PhD, MPH, Karla K. Quevedo, MD, Siddharth Singh, MD

Planner, reviewer, and editor-in-chief: Debabrata Mukherjee, MD, MS, FACC

PER planners and staff: Ann C. Lichti, CCMEP, Megan O’Connell, Emily Valko, and Jackie Syrop

Cardiology Review staff: Bea Riemschneider

Provider Contact Information:

Physicians’ Education Resource®, LLC

666 Plainsboro Road, Suite 356

Plainsboro, NJ 08536

Toll Free: 888-949-0045

Local: 609-378-3701

Fax: 609-257-0705

info@gotoper.com

Related Videos
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
Orly Vardeny, PharmD | Credit: JACC Journals
© 2024 MJH Life Sciences

All rights reserved.